Home
GILD
GILD News

Latest Gilead Sciences Inc. (GILD) News on October 22, 2025

LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

CNW Group

a day ago

LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

Business Wire

a day ago

AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP

MT Newswires

2 days ago

BMO Capital Adjusts Price Target on Gilead Sciences to $135 From $130, Maintains Outperform Rating

Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

Business Wire

3 days ago

Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

Business Wire

3 days ago

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial Results

Simply Wall St.

5 days ago

A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial Results

MT Newswires

5 days ago

Goldman Sachs Raises Gilead Sciences Price Target to $108 From $105, Neutral Rating Maintained

Stock Market Today: Dow Up Amid Bank Fears; Eli Lilly, Novo Sell Off On Trump Comments (Live Coverage)

Investor's Business Daily

5 days ago

Stock Market Today: Dow Up Amid Bank Fears; Eli Lilly, Novo Sell Off On Trump Comments (Live Coverage)

RBC Warns Gilead (GILD) Faces Risk from Trump’s Price Cut Target

Insider Monkey

6 days ago

RBC Warns Gilead (GILD) Faces Risk from Trump’s Price Cut Target

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks

6 days ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

Business Wire

7 days ago

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

Gilead and Arcus reignite anti-TIGIT interest with Phase II gastric cancer win

Clinical Trials Arena

8 days ago

Gilead and Arcus reignite anti-TIGIT interest with Phase II gastric cancer win

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025

Business Wire

9 days ago

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025

MT Newswires

9 days ago

Arcus Says Combination Therapy Shows 26.7 Months Median Survival in Gastroesophageal Cancer

How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline

Simply Wall St.

11 days ago

How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline

How the Story Behind Gilead Is Evolving in Light of Key Analyst and Industry Updates

Simply Wall St.

11 days ago

How the Story Behind Gilead Is Evolving in Light of Key Analyst and Industry Updates

3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR

Zacks

12 days ago

3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR

Morningstar Research

12 days ago

Analyst Report: Gilead Sciences, Inc.

3 S&P 500 Stocks We Approach with Caution

StockStory

12 days ago

3 S&P 500 Stocks We Approach with Caution

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Business Wire

13 days ago

Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

GlobeNewswire

13 days ago

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD

Business Wire

13 days ago

Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD

MT Newswires

13 days ago

Cantor Fitzgerald Adjusts PT on Gilead Sciences to $135 From $129, Maintains Overweight Rating

Gilead Sciences Rallies After Trump Partnership News Is the Growth Story Just Beginning

Simply Wall St.

14 days ago

Gilead Sciences Rallies After Trump Partnership News Is the Growth Story Just Beginning

MT Newswires

14 days ago

Citigroup Adjusts Price Target on Gilead Sciences to $135 From $125, Maintains Buy Rating

MT Newswires

14 days ago

RBC Lifts Price Target on Gilead Sciences to $100 From $98, Keeps Sector Perform Rating

Gilead Resolves Patent Litigations for HIV Treatment Biktarvy

Zacks

15 days ago

Gilead Resolves Patent Litigations for HIV Treatment Biktarvy

Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump

Investor's Business Daily

16 days ago

Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump

MT Newswires

16 days ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

16 days ago

Sector Update: Health Care Stocks Softer Monday Afternoon

MT Newswires

16 days ago

Gilead Sciences Settles Biktarvy Patent Lawsuits With Generic Drug Makers

Investing.com

16 days ago

Gilead stock rises after settling Biktarvy patent disputes

2 Surefire Dividend Stocks to Buy for the Long Haul

Motley Fool

18 days ago

2 Surefire Dividend Stocks to Buy for the Long Haul

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Zacks

19 days ago

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD)

Insider Monkey

19 days ago

RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD)

Gilead Foundation Commits Over $6.5M in New Grant Funding to Support STEM Education Pathways

Insider Monkey

19 days ago

Gilead Foundation Commits Over $6.5M in New Grant Funding to Support STEM Education Pathways

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Zacks

20 days ago

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead’s Lost Decade Is Over. It’s Time to Buy the Stock.

Barrons.com

20 days ago

Gilead’s Lost Decade Is Over. It’s Time to Buy the Stock.

Trump Triggered a Rally in Drug Stocks. Why It Might Not Last.

Barrons.com

21 days ago

Trump Triggered a Rally in Drug Stocks. Why It Might Not Last.

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline

Zacks

21 days ago

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline

Immatics Appoints Venkat Ramanan as Chief Financial Officer

GlobeNewswire

21 days ago

Immatics Appoints Venkat Ramanan as Chief Financial Officer

2 Nasdaq 100 Stocks on Our Watchlist and 1 We Brush Off

StockStory

22 days ago

2 Nasdaq 100 Stocks on Our Watchlist and 1 We Brush Off

MT Newswires

22 days ago

Gilead Sciences Insider Sold Shares Worth $1,116,564, According to a Recent SEC Filing

What Do Analysts Think About Gilead Sciences (GILD)?

Insider Monkey

22 days ago

What Do Analysts Think About Gilead Sciences (GILD)?

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

PR Newswire

23 days ago

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

Hanmi's Oral Delivery Platform Compound Licensed to Gilead

PR Newswire

23 days ago

Hanmi's Oral Delivery Platform Compound Licensed to Gilead

Morgan Stanley Maintains Buy on Gilead Sciences (GILD)

Insider Monkey

23 days ago

Morgan Stanley Maintains Buy on Gilead Sciences (GILD)

3 Unpopular Stocks We Approach with Caution

StockStory

24 days ago

3 Unpopular Stocks We Approach with Caution

Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum

Insider Monkey

25 days ago

Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum

JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating

Insider Monkey

a month ago

JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors

Zacks

a month ago

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors

Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category

Insider Monkey

a month ago

Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category

Gilead Foundation Grants $6.5 Million in Commitment to STEM Education

Business Wire

a month ago

Gilead Foundation Grants $6.5 Million in Commitment to STEM Education

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?

Zacks

a month ago

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?

MT Newswires

a month ago

Dr. Reddy's Laboratories, Hetero to Offer $40 Generic HIV Prevention Shot by 2027

Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors

Business Wire

a month ago

Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

Business Wire

a month ago

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

Did Gilead's (GILD) $32 Billion AI Bet Just Transform Its Innovation and Global Health Narrative?

Simply Wall St.

a month ago

Did Gilead's (GILD) $32 Billion AI Bet Just Transform Its Innovation and Global Health Narrative?

Gilead Sciences, Inc. (GILD) Expands U.S. Manufacturing Capacity With $32B Investment Through 2030

Insider Monkey

a month ago

Gilead Sciences, Inc. (GILD) Expands U.S. Manufacturing Capacity With $32B Investment Through 2030

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Zacks

a month ago

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Zacks

a month ago

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer

PR Newswire

a month ago

Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer

Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management

GlobeNewswire

a month ago

Fangzhou Wins Gilead ‘Award of Excellence’ for AI-Driven Chronic Disease Management

Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note

Zacks

a month ago

Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

GlobeNewswire

a month ago

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $340,710, According to a Recent SEC Filing

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $283,925, According to a Recent SEC Filing

Redburn Atlantic Maintains a Buy on Gilead Sciences (GILD), Sets a $143 PT

Insider Monkey

a month ago

Redburn Atlantic Maintains a Buy on Gilead Sciences (GILD), Sets a $143 PT

Top 20 Companies Recognized in Labrador Transparency’s 2025 U.S. Transparency Awards

Business Wire

a month ago

Top 20 Companies Recognized in Labrador Transparency’s 2025 U.S. Transparency Awards

MT Newswires

a month ago

JPMorgan Adjusts Price Target on Gilead Sciences to $145 From $135, Maintains Overweight Rating

3 Reasons GILD is Risky and 1 Stock to Buy Instead

StockStory

a month ago

3 Reasons GILD is Risky and 1 Stock to Buy Instead

Alger Russell Innovation Index Updates for Third Quarter 2025

PR Newswire

a month ago

Alger Russell Innovation Index Updates for Third Quarter 2025

Why California’s biopharma boom is critical for logistics

FreightWaves

a month ago

Why California’s biopharma boom is critical for logistics

Investing.com

a month ago

Biotech stocks: Who wins and who loses if RFK, Jr. goes

Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock

Benzinga

a month ago

Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock

MT Newswires

a month ago

Rothschild & Co Redburn Adjusts Gilead Sciences Price Target to $143 From $136, Maintains Buy Rating

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

Zacks

a month ago

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

Biotechs Could Benefit If RFK Jr. Leaves HHS

GuruFocus.com

a month ago

Biotechs Could Benefit If RFK Jr. Leaves HHS

Gilead Sciences Commits To Veeva Systems (VEEV) For Vault CRM Suite

Simply Wall St.

a month ago

Gilead Sciences Commits To Veeva Systems (VEEV) For Vault CRM Suite

The ELC Awards $2 Million in Scholarships to More Than 100 Emerging Business Leaders in 2025 Cohort

PR Newswire

a month ago

The ELC Awards $2 Million in Scholarships to More Than 100 Emerging Business Leaders in 2025 Cohort

MT Newswires

a month ago

Veeva Systems Expands Partnership With Gilead Sciences

Gilead Sciences Commits to Veeva Vault CRM

PR Newswire

a month ago

Gilead Sciences Commits to Veeva Vault CRM

Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating

Insider Monkey

a month ago

Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating

MT Newswires

a month ago

Xilio Therapeutics Starts Phase 2 Trial for Potential Anti-Tumor Monotherapy, Achieves $17.5 Million Development Milestone Under License Deal With Gilead

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Business Wire

a month ago

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

What the Trump Administration Partnership Means for Gilead Sciences Shares in 2025

Simply Wall St.

a month ago

What the Trump Administration Partnership Means for Gilead Sciences Shares in 2025

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

GlobeNewswire

a month ago

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

Hepatitis D Market Research Report 2023-2035 | Gilead, GSK, and Janssen Drive Innovation as Biotechs Advance Antivirals, RNA, and Gene Therapies

GlobeNewswire

a month ago

Hepatitis D Market Research Report 2023-2035 | Gilead, GSK, and Janssen Drive Innovation as Biotechs Advance Antivirals, RNA, and Gene Therapies

WACO Theater Center Announces Still Here Live Experience In Los Angeles Supported By Gilead Sciences, Inc.

PR Newswire

a month ago

WACO Theater Center Announces Still Here Live Experience In Los Angeles Supported By Gilead Sciences, Inc.

MT Newswires

a month ago

Ideaya Reports 'Positive' Initial Data on Trodelvy Combination Trial in Urothelial Cancer

Argus Research

a month ago

Weekly Stock List

Leerink Partners Maintains Buy on Gilead Sciences (GILD)

Insider Monkey

a month ago

Leerink Partners Maintains Buy on Gilead Sciences (GILD)

Gilead Acquires Interius BioTherapeutics to Advance Next-Gen Cell Therapy

Insider Monkey

2 months ago

Gilead Acquires Interius BioTherapeutics to Advance Next-Gen Cell Therapy

Gilead Sciences advances HIV prevention with new US partnership

Pharmaceutical Technology

2 months ago

Gilead Sciences advances HIV prevention with new US partnership

The US will buy 2 million doses of an HIV prevention drug for low-income countries

Associated Press Finance

2 months ago

The US will buy 2 million doses of an HIV prevention drug for low-income countries

MT Newswires

2 months ago

Gilead Sciences Collaborates With PEPFAR to Make HIV Drug Lenacapavir Accessible Across Countries

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Business Wire

2 months ago

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

Insider Monkey

2 months ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer

GlobeNewswire

2 months ago

Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer

Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva

GlobeNewswire

2 months ago

Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva

Share on Social Networks: